GoAI
Get started
Stereotaxis, Inc. logo

Stereotaxis, Inc.

STXS

AMEXHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$1.42

−$0.02 · -1.39%

Aug 21, 4:00 PM ET

STXS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

67

Undervalued

Momentum

28

Weakening

Sentiment

55

Mixed

Risk resilience

26

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
David L. Fischel
Listed since
Aug 12, 2004
Employees
131

Market position

Day range

Current $1.42

52-week range

Current $1.42

Open
$1.46
Previous close
$1.44
Volume
357.84K
0.51× average
Average volume
695.71K
Average daily volume
Market cap
139.07M USD
Beta
1.4
Market reference 1
50-day average
$1.5636
-9.18% below average
200-day average
$2.0084
-29.30% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
201.22M USD
EV / EBITDA
-10.02×
Earnings yield
-10.35%
Free cash flow yield
-6.59%

Profitability & efficiency

Return on equity
-115.61%
Return on assets
-41.42%
Return on invested capital
-72.42%

Financial health

Current ratio
1.51×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%19%-44%-108%Gross margin, FY2021: 66.34%Gross margin, FY2022: 65.62%Gross margin, FY2023: 55.51%Gross margin, FY2024: 54.22%Gross margin, FY2025: 52.73%Operating margin, FY2021: -36.80%Operating margin, FY2022: -66.71%Operating margin, FY2023: -81.58%Operating margin, FY2024: -91.91%Operating margin, FY2025: -68.30%Net margin, FY2021: -30.60%Net margin, FY2022: -64.99%Net margin, FY2023: -77.37%Net margin, FY2024: -89.33%Net margin, FY2025: -66.85%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 66.34%. Gross margin FY2022 65.62%. Gross margin FY2023 55.51%. Gross margin FY2024 54.22%. Gross margin FY2025 52.73%. Operating margin FY2021 -36.80%. Operating margin FY2022 -66.71%. Operating margin FY2023 -81.58%. Operating margin FY2024 -91.91%. Operating margin FY2025 -68.30%. Net margin FY2021 -30.60%. Net margin FY2022 -64.99%. Net margin FY2023 -77.37%. Net margin FY2024 -89.33%. Net margin FY2025 -66.85%.

Income trends

Revenue

32.38M USD+20.28%

Operating income

−22.11M USD+10.62%

Net income

−21.64M USD+9.99%
Income trends across reported periods41M USD17.09M USD−6.81M USD−30.72M USDRevenue, FY2021: 35.02M USDRevenue, FY2022: 28.15M USDRevenue, FY2023: 26.77M USDRevenue, FY2024: 26.92M USDRevenue, FY2025: 32.38M USDOperating income, FY2021: −12.89M USDOperating income, FY2022: −18.78M USDOperating income, FY2023: −21.84M USDOperating income, FY2024: −24.74M USDOperating income, FY2025: −22.11M USDNet income, FY2021: −10.72M USDNet income, FY2022: −18.29M USDNet income, FY2023: −20.71M USDNet income, FY2024: −24.05M USDNet income, FY2025: −21.64M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 35.02M USD. Revenue FY2022 28.15M USD. Revenue FY2023 26.77M USD. Revenue FY2024 26.92M USD. Revenue FY2025 32.38M USD. Operating income FY2021 −12.89M USD. Operating income FY2022 −18.78M USD. Operating income FY2023 −21.84M USD. Operating income FY2024 −24.74M USD. Operating income FY2025 −22.11M USD. Net income FY2021 −10.72M USD. Net income FY2022 −18.29M USD. Net income FY2023 −20.71M USD. Net income FY2024 −24.05M USD. Net income FY2025 −21.64M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue32.38M USD26.92M USD26.77M USD28.15M USD35.02M USD
Cost of goods sold15.31M USD12.32M USD11.91M USD9.68M USD11.79M USD
Gross profit17.07M USD14.59M USD14.86M USD18.47M USD23.23M USD
Research and development9.38M USD9.76M USD10.27M USD10.56M USD10.2M USD
Selling, general, and administrative30.29M USD29.57M USD26.43M USD26.69M USD25.92M USD
Operating expenses39.18M USD39.33M USD36.7M USD37.25M USD36.12M USD
Interest income467K USD694K USD1.1M USD484K USD—
Interest expense————10.07K USD
Depreciation and amortization1.56M USD969K USD595K USD429K USD106K USD
Operating income−22.11M USD−24.74M USD−21.84M USD−18.78M USD−12.89M USD
Net income−21.64M USD−24.05M USD−20.71M USD−18.29M USD−10.72M USD

Company facts updated Aug 24, 2026.

STXS news

seekingalpha.com

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Stereotaxis Q2 Earnings Call Highlights

Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and…

Read source
zacks.com

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.

Read source
globenewswire.com

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial…

Read source
globenewswire.com

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release…

Read source
globenewswire.com

University of Szeged Pioneers First Robotic Cardiology Program in Hungary

First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using…

Read source

Corporate actions

Corporate action history

Stock split

Effective Nov 4, 2013

137:125

Stock split

Effective Jul 11, 2012

1:10

STXS peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

—

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

—

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

—

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

—

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

—

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

—

ETFs holding STXS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.5M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
2.32M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.24M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
921.97K
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
482.27K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
333.36K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
96.55K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
45.96K
Weight
—
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%

Continue in GoAI

Research STXS

research.disclaimer